Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Zentalis Pharmaceuticals ( (ZNTL) ) has provided an update.
On January 6, 2026, Zentalis Pharmaceuticals provided a corporate update highlighting 2025 progress and outlining key 2026 milestones for its azenosertib program in Cyclin E1-positive platinum-resistant ovarian cancer. In 2025, the company completed enrollment in Part 2a of its Phase 2 DENALI trial to confirm the dose for registration-intended studies, aligned with the U.S. Food and Drug Administration on the design of ASPENOVA, a randomized Phase 3 confirmatory trial versus standard chemotherapy in Cyclin E1-positive PROC, and reported strong data across three PROC studies, including clinically meaningful efficacy and a manageable safety profile at 400 mg once daily on a 5:2 schedule. Zentalis also reported holding $280.7 million in cash, cash equivalents and marketable securities as of September 30, 2025, which it expects to fund operations into late 2027 following a pipeline-focused restructuring, and it set 2026 targets that include DENALI Part 2a dose confirmation and ASPENOVA trial initiation in the first half of the year, as well as a DENALI Part 2 topline readout by year-end 2026 that could be pivotal for the company’s regulatory path and competitive positioning in ovarian cancer therapeutics.
The most recent analyst rating on (ZNTL) stock is a Hold with a $3.00 price target. To see the full list of analyst forecasts on Zentalis Pharmaceuticals stock, see the ZNTL Stock Forecast page.
Spark’s Take on ZNTL Stock
According to Spark, TipRanks’ AI Analyst, ZNTL is a Neutral.
The score is primarily weighed down by weak financial performance driven by large operating losses and significant cash burn, despite strong gross margins and some revenue traction. Technicals are supportive in the near term with price above key moving averages and positive MACD, but extreme overbought readings raise reversal risk. Valuation is also constrained by a negative P/E and no dividend support.
To see Spark’s full report on ZNTL stock, click here.
More about Zentalis Pharmaceuticals
Zentalis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing targeted, orally available oncology therapies, with its lead candidate azenosertib (ZN-c3) being advanced primarily for Cyclin E1-positive platinum-resistant ovarian cancer (PROC). The company is pursuing a biomarker-driven strategy around Cyclin E1 overexpression and, following a strategic restructuring, is concentrating resources on late-stage, registration-intent development of azenosertib while maintaining a cash runway that it estimates extends into late 2027.
Average Trading Volume: 1,005,535
Technical Sentiment Signal: Sell
Current Market Cap: $174.8M
For detailed information about ZNTL stock, go to TipRanks’ Stock Analysis page.